Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256671 · ClinicalTrials.gov registry record · Phase 3
DHEA Against Vaginal Atrophy - Safety Study of 12 Months
A Phase 3 study, sponsored by EndoCeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT01256671 is a Phase 3 study that has completed, run by EndoCeutics. The registered enrollment target is 530 participants.
The verdict
NCT01256671, a Phase 3 study, has completed, sponsored by EndoCeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.
Interventions
- DRUG DHEA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01256671
The ClinicalTrials.gov registry entry for NCT01256671 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EndoCeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DHEA is the first listed.
NCT01256671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01256671 about?
NCT01256671 is a clinical study titled "DHEA Against Vaginal Atrophy - Safety Study of 12 Months". The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.
What is the current status of trial NCT01256671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2010-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01256671?
The interventions under investigation include: DHEA (DRUG).
Who is sponsoring clinical trial NCT01256671?
This trial is sponsored by EndoCeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.